Method of regulating the female reproductive system through angiogenesis inhibitors

Abstract

A method of inhibiting angiogenesis in a female mammal to regulate fertility comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. In addition, a method of inhibiting angiogenesis in a female mammal to treat a disease or condition of the reproductive tissue that is mediated by angiogenesis comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. AGM-1470 is provided as such an angiogenesis inhibiting compound.

We claim:  
     
         1 . A method of inhibiting angiogenesis in a female mammal to regulate fertility comprising administering to the female mammal an effective amount of a fertility regulating angiogenesis inhibiting compound, thereby inhibiting angiogenesis in the female mammal to regulate fertility.  
     
     
         2 . The method of  claim 1 , wherein the angiogenesis inhibiting compound is administered to prevent conception.  
     
     
         3 . The method of  claim 1 , wherein the angiogenesis inhibiting compound is administered to terminate a pregnancy.  
     
     
         4 . The method of  claim 1 , wherein angiogenesis is inhibited in the uterus, ovary, placenta or fetus.  
     
     
         5 . The method of  claim 1 , wherein the angiogenesis inhibiting compound is AGM-1470.  
     
     
         6 . The method of  claim 1 , wherein the angiogenesis inhibiting compound is an antagonist of the AGM-1470 receptor MetAP-2.  
     
     
         7 . The method of  claim 1 , wherein the angiogenesis inhibiting compound is administered in a single dose or in multiple doses.  
     
     
         8 . The method of  claim 1 , wherein angiogenesis is inhibited prior to, during, or after decidualization, placental formation, yolk sac or fetal development.  
     
     
         9 . The method of  claim 1 , wherein the angiogenesis inhibiting compound is administered prior to intercourse, after intercourse or after ovum fertilization.  
     
     
         10 . A method of inhibiting angiogenesis in a female mammal to treat a disease or condition of the reproductive tissue that is mediated by angiogenesis comprising administering to the female mammal an effective amount of a female reproductive tissue angiogenesis inhibiting compound, thereby inhibiting angiogenesis in a female mammal to treat the disease or condition of the reproductive tissue.  
     
     
         11 . The method of  claim 10 , wherein the angiogenesis mediated disease or condition is endometriosis, adenomyosis, dysfunctional uterine bleeding, uterine leiomyoma, an ovarian cyst, choriocarcinoma or ectopic pregnancy.  
     
     
         12 . The method of  claim 10 , wherein angiogenesis is inhibited in the uterus, ovary, placenta, fetus or ectopic tissue originating from the uterus or ovary.  
     
     
         13 . The method of  claim 10 , wherein the angiogenesis inhibiting compound is AGM-1470.  
     
     
         14 . The method of  claim 10 , wherein the angiogenesis inhibiting compound is an antagonist of the AGM-1470 receptor MetAP-2.  
     
     
         15 . The method of  claim 10 , wherein the angiogenesis inhibiting compound is administered in a single dose or in multiple doses.